Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIRID: High-dose Ribavirin in HCV
NCT00662220Phase 3Terminated
- Sponsor
- Foundation for Liver Research
- Start
- Apr 2008
- Primary completion
- Jun 2013
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ribavirin in hepatitis C (HCV) (2 arms), sponsored by Foundation for Liver Research. Primary endpoint: Sustained Virological Response at 72 weeks. Started Apr 2008; status: terminated.
02
Drugs
ribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00662220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00662220.